Added Value of Clinical Sequencing: WGS-Based Profiling of Pharmacogenes

Although several pharmacogenetic (PGx) predispositions affecting drug efficacy and safety are well established, drug selection and dosing as well as clinical trials are often performed in a non-pharmacogenetically-stratified manner, ultimately burdening healthcare systems. Pre-emptive PGx testing offers a solution which is often performed using microarrays or targeted gene panels, testing for common/known PGx variants. However, as an added value, whole-genome sequencing (WGS) could detect not only disease-causing but also pharmacogenetically-relevant variants in a single assay. Here, we present our WGS-based pipeline that extends the genetic testing of Mendelian diseases with PGx profiling, enabling the detection of rare/novel PGx variants as well. From our in-house WGS (PCR-free 60× PE150) data of 547 individuals we extracted PGx variants with drug-dosing recommendations of the Dutch Pharmacogenetics Working Group (DPWG). Furthermore, we explored the landscape of DPWG pharmacogenes in gnomAD and our in-house cohort as well as compared bioinformatic tools for WGS-based structural variant detection in CYP2D6. We show that although common/known PGx variants comprise the vast majority of detected DPWG pharmacogene alleles, for better precision medicine, PGx testing should move towards WGS-based approaches. Indeed, WGS-based PGx profiling is not only feasible and future-oriented but also the most comprehensive all-in-one approach without generating significant additional costs.

[1]  Jeffrey C. Hall,et al.  The CLIPMERGE PGx Program: Clinical Implementation of Personalized Medicine Through Electronic Health Records and Genomics–Pharmacogenomics , 2013, Clinical pharmacology and therapeutics.

[2]  Rémy Bruggmann,et al.  Need for speed in accurate whole-genome data analysis: GENALICE MAP challenges BWA/GATK more than PEMapper/PECaller and Isaac , 2017, Proceedings of the National Academy of Sciences.

[3]  Leah E. Mechanic,et al.  Pharmacogenomics in oncology care , 2014, Front. Genet..

[4]  Russ B Altman,et al.  PharmGKB: the Pharmacogenomics Knowledge Base. , 2013, Methods in molecular biology.

[5]  Yitian Zhou,et al.  Integrating rare genetic variants into pharmacogenetic drug response predictions , 2018, Human Genomics.

[6]  Ulrich Broeckel,et al.  Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project. , 2016, The Journal of molecular diagnostics : JMD.

[7]  Rémy Bruggmann,et al.  Clinical sequencing: is WGS the better WES? , 2016, Human Genetics.

[8]  D. Nickerson,et al.  Calling Star Alleles With Stargazer in 28 Pharmacogenes With Whole Genome Sequences , 2019, Clinical pharmacology and therapeutics.

[9]  R. Vossen,et al.  Flexible and Scalable Full‐Length CYP2D6 Long Amplicon PacBio Sequencing , 2017, Human mutation.

[10]  Paul Scheet,et al.  A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. , 2006, American journal of human genetics.

[11]  Jean-François Zagury,et al.  Shape-IT: new rapid and accurate algorithm for haplotype inference , 2008, BMC Bioinformatics.

[12]  David G. Knowles,et al.  Fast Computation and Applications of Genome Mappability , 2012, PloS one.

[13]  Neil A. Miller,et al.  Constellation: a tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene, CYP2D6, from whole-genome sequences , 2016, npj Genomic Medicine.

[14]  R. W. Hansen,et al.  Journal of Health Economics , 2016 .

[15]  Rémy Bruggmann,et al.  New insights into the performance of human whole-exome capture platforms , 2015, Nucleic acids research.

[16]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[17]  B. Berger,et al.  Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes , 2018, Nature Communications.

[18]  M O Karlsson,et al.  Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium , 2017, Clinical pharmacology and therapeutics.

[19]  A. Najafi,et al.  Variant filtering, digenic variants, and other challenges in clinical sequencing: a lesson from fibrillinopathies , 2019, Clinical genetics.

[20]  P. Stenson,et al.  The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine , 2013, Human Genetics.

[21]  Semyon Kruglyak,et al.  Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms , 2013, Bioinform..

[22]  Hong Xu,et al.  Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project , 2018, J. Am. Medical Informatics Assoc..

[23]  R. Fulton,et al.  PGRNseq: a targeted capture sequencing panel for pharmacogenetic research and implementation , 2016, Pharmacogenetics and genomics.

[24]  T. Klein,et al.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.

[25]  S. Colan,et al.  Atenolol versus losartan in children and young adults with Marfan's syndrome. , 2014, The New England journal of medicine.

[26]  Jeffrey L. Anderson,et al.  Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial , 2017, JAMA.

[27]  J. Hirsch,et al.  Cost of Prescription Drug–Related Morbidity and Mortality , 2018, The Annals of pharmacotherapy.

[28]  M. Ingelman-Sundberg,et al.  Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response , 2016, Genetics in Medicine.

[29]  M. Schwab,et al.  Copy number variation profiling in pharmacogenes using panel-based exome resequencing and correlation to human liver expression , 2019, Human Genetics.

[30]  Andrea Gaedigk,et al.  Characterization of Reference Materials for Genetic Testing of CYP2D6 Alleles A GeT-RM Collaborative Project. , 2019, The Journal of molecular diagnostics : JMD.

[31]  J. Pearson,et al.  Nanopore sequencing of the pharmacogene CYP2D6 allows simultaneous haplotyping and detection of duplications , 2019, bioRxiv.

[32]  R. Sebra,et al.  Long‐Read Single Molecule Real‐Time Full Gene Sequencing of Cytochrome P450‐2D6 , 2016, Human mutation.

[33]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.

[34]  Shufeng Zhou.  Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance , 2009, Clinical pharmacokinetics.

[35]  Christopher T. Saunders,et al.  Strelka2: fast and accurate calling of germline and somatic variants , 2018, Nature Methods.

[36]  Jamie Munro,et al.  Trends in clinical success rates and therapeutic focus , 2019, Nature Reviews Drug Discovery.

[37]  S M Caspar,et al.  Clinical sequencing: From raw data to diagnosis with lifetime value , 2018, Clinical genetics.

[38]  Mauricio O. Carneiro,et al.  From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.

[39]  Suzette J. Bielinski,et al.  Design and Anticipated Outcomes of the eMERGE-PGx Project: A Multi-Center Pilot for Pre-Emptive Pharmacogenomics in Electronic Health Record Systems , 2014, Clinical pharmacology and therapeutics.

[40]  Deanna M. Church,et al.  ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..

[41]  M. Ingelman-Sundberg,et al.  Development of the PGx‐Passport: A Panel of Actionable Germline Genetic Variants for Pre‐Emptive Pharmacogenetic Testing , 2019, Clinical pharmacology and therapeutics.

[42]  D. Sica,et al.  Clinical Pharmacokinetics of Losartan , 2005, Clinical pharmacokinetics.

[43]  B. Browning,et al.  Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. , 2007, American journal of human genetics.

[44]  Marc K. Halushka,et al.  Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.

[45]  R. Mägi,et al.  Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions , 2018, Genetics in Medicine.

[46]  Jacques Fellay,et al.  The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. , 2008, The Journal of infectious diseases.